Monoclonal anti-CD4 as immunoprophylactic agents for human immunodeficiency virus infection.
Monoclonal anti-CD4 as immunoprophylactic agents for human immunodeficiency virus infection.
复制标题
单克隆抗 CD4 作为人类免疫缺陷病毒感染的免疫预防剂。
DOI：
10.1093/infdis/168.2.515
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Kennedy,RC
中科院分区：
文献类型：
--
作者：
Attanasio,R;Allan,JS;Kennedy,RC
同事们——针对人类免疫缺陷病毒（HIV）感染的被动免疫预防可能是一种非常有价值的控制策略，可以防止意外接触引起的感染，并阻止受感染母亲在出生时垂直传播给后代。 Leu-3a 是一种高亲和力小鼠单克隆抗 CD4 抗体，可在体外抑制 HIV gp120/CD4 结合以及 HIV 和猿猴免疫缺陷病毒 (SIV) 合胞体形成 [1]，可用于阻断体内病毒受体相互作用并防止病毒传播到未感染的细胞。由于所有 HIV 和 SIV 分离株与易感细胞的初始结合步骤都是通过病毒与 CD4 分子相同区域的相互作用发生的，因此 Leu-3a 可能对多种 HIV 毒株有效。与其他针对病毒的潜在免疫预防剂相比，这代表了巨大的优势。后者包括HIV超免疫球蛋白(HIVIG)、CD4免疫粘附素和抗HIV中和单克隆抗体，已被证明可以在体外和动物模型中预防HIV-1感染[2]。然而，使用直接针对病毒的制剂存在一些问题。例如，由于免疫球蛋白池中可能存在增强抗体，HIVIG 人体试验已被推迟。进一步的担忧与 HIVIG 对世界各地出现的所有不同 HIV-1 病毒株的有效性有关。
Colleagues-Passive immunoprophylaxis for human immunodeficiency virus (HIV) infection may represent an extremely valuable control strategy to prevent infection by accidental exposure and to interrupt vertical transmission from infected mothers to their offspring at birth. Leu-3a, a high-affinity mouse monoclonal anti-CD4 antibody that inhibits HIV gp120/CD4 binding in vitro as well as HIV and simian immunodeficiency virus (SIV) syncytium formation [1] might be used to block the viral receptor interaction in vivo and prevent virus spread to uninfected cells. Since the initial binding step ofall HIV and SIV isolates to susceptible cells occurs through the interaction of the virus with the same region of the CD4 molecule, Leu-3a might be effective against a wide range of HIV strains. This represents a substantial advantage compared with other potential immunoprophylactic agents that target the virus. These latter agents, which include HIV hyperimmune globulin (HIVIG), CD4 immunoadhesins, and anti-HIV neutralizing monoclonal antibodies, have been shown to prevent HIV-l infection both in vitro and in animal models [2]. However, several problems are associated with the use of preparations that directly target the virus. As an example, HIVIG human trials have been delayed because of the potential presence of enhancing antibodies within the immunoglobulin pool. Further concerns are related to the effectiveness of HIVIG against all different HIV-1 strains that occur worldwide.